Active Ingredient History
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acne Vulgaris (Phase 3)
Alzheimer Disease (Phase 2)
BCG Vaccine (Phase 4)
Biological Availability (Phase 1)
Breast Neoplasms (Phase 2)
Cognition (Phase 4)
Drug Delivery Systems (Phase 4)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 1)
Flank Pain (Phase 4)
Healthy Volunteers (Phase 1)
Hot Flashes (Phase 2)
Lower Urinary Tract Symptoms (Phase 4)
Multiple Sclerosis (Phase 4)
Nocturia (Phase 4)
Parkinson Disease (Phase 4)
Pelvic Organ Prolapse (Phase 4)
Pharmacokinetics (Phase 4)
Pharmacology (Phase 1)
Postmenopause (Phase 4)
Prostatic Hyperplasia (Phase 4)
Prostatic Neoplasms (Phase 4)
Quality of Life (Phase 2/Phase 3)
Signs and Symptoms (Phase 2)
Sjogren's Syndrome (Phase 4)
Spinal Cord Diseases (Phase 4)
Stents (Phase 3)
Transurethral Resection of Prostate (Phase 4)
Ureteral Diseases (Phase 4)
Urinary Bladder (Phase 4)
Urinary Bladder Diseases (Phase 4)
Urinary Bladder Neck Obstruction (Phase 2)
Urinary Bladder Neoplasms (Phase 4)
Urinary Bladder, Neurogenic (Phase 4)
Urinary Bladder, Underactive (Phase 2)
Urinary Incontinence (Phase 4)
Urinary Incontinence, Stress (Phase 4)
Urinary Incontinence, Urge (Phase 4)
Urinary Tract Infections (Phase 4)
Urination Disorders (Phase 4)
Urodynamics (Phase 4)
Urological Manifestations (Phase 2)
Urologic Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
